Skip to Main Content

Paper Details

Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Ann Neurol
99
2019
3K3A, 3K3A-APC, APC, Acute Ischemic Stroke, Human, Human Activated Protein C, ICH, PAR1, Tissue Plasminogen Activator, activated protein C, acute ischemic stroke, hemorrhage, human, intracranial hemorrhage, ischemic stroke, neuroinjury, neurological injury, patients, protease-activated receptor (PAR) 1, stroke, tissue plasminogen activator
Author NameAffiliation
Christopher S CoffeyThe University of Iowa
Robin ConwitNational Institutes of Health, National Institute of Neurological Disorders and Stroke
Ashutosh P JadhavUniversity of Pittsburgh Medical School
Jan ClaassenNeurological Institute, Columbia University
Opeolu AdeoyeUniversity of Cincinnati
Natalia S RostMassachusetts General Hospital, Neurological Clinical Research Institute
Michael T FroehlerVanderbilt University Medical Center
Howard Levy
Arthur W TogaInstitute of Neuroimaging and Informatics, Keck School of Medicine, University of Southern California Los Angeles
Arthur W TogaInstitute of Neuroimaging and Informatics, Keck School of Medicine, University of Southern California Los Angeles
  • 1 - 10

Datasets

Release 1.2